Literature DB >> 9236744

Evaluation of different techniques in the diagnosis of Toxoplasma encephalitis.

J C Rodríguez1, M M Martínez, A R Martínez, G Royo.   

Abstract

This study evaluated the detection of antibodies, circulating antigens and parasite DNA by polymerase chain reaction (PCR) in the diagnosis of toxoplasma encephalitis. The detection of antibody classes and IgG avidity were not useful diagnostically. The detection of circulating antigens by the ELISA system described was not sufficiently sensitive. The detection of DNA by PCR was the most useful test especially in untreated patients, with a sensitivity of 62% overall, 81% in untreated patients and only 20% in treated patients. The use of non-isotopic probes makes the use of this technique feasible in routine diagnostic parasitology laboratories.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9236744     DOI: 10.1099/00222615-46-7-597

Source DB:  PubMed          Journal:  J Med Microbiol        ISSN: 0022-2615            Impact factor:   2.472


  4 in total

1.  Value of PCR for detection of Toxoplasma gondii in aqueous humor and blood samples from immunocompetent patients with ocular toxoplasmosis.

Authors:  G Bou; M S Figueroa; P Martí-Belda; E Navas; A Guerrero
Journal:  J Clin Microbiol       Date:  1999-11       Impact factor: 5.948

2.  PCR assay using cerebrospinal fluid for diagnosis of cerebral toxoplasmosis in Brazilian AIDS patients.

Authors:  José E Vidal; Fabio Antonio Colombo; Augusto C Penalva de Oliveira; Roberto Focaccia; Vera Lucia Pereira-Chioccola
Journal:  J Clin Microbiol       Date:  2004-10       Impact factor: 5.948

3.  Development of a PCR-enzyme immunoassay oligoprobe detection method for Toxoplasma gondii oocysts, incorporating PCR controls.

Authors:  Kellogg J Schwab; James J McDevitt
Journal:  Appl Environ Microbiol       Date:  2003-10       Impact factor: 4.792

4.  Central Nervous System Toxoplasmosis in HIV Pathogenesis, Diagnosis, and Therapy.

Authors: 
Journal:  Curr Infect Dis Rep       Date:  2000-08       Impact factor: 3.663

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.